MD News - HIPEC: Furthering Survivorship for GYN Cancer Patients

MD News - HIPEC: Furthering Survivorship for GYN Cancer Patients

Monday, March 12, 2012

A team of cancer specialists at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center is among the first in the nation to launch a dedicated gynecologic program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other malignancies.

 Q: What is HIPEC, and how is it delivered?
Q: What are the advantages of HIPEC over traditional IV chemotherapy?
Q: I understand UH is planning several research studies on HIPEC. What will they involve?
Q: What do you want physicians to know about HIPEC?
   

( Italy) Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence - Full Text View - ClinicalTrials.gov

Official Title:
Surgery Plus Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Versus Surgery Alone in Patients With Platinum-sensitive First
Recurrence of Ovarian Cancer: a Prospective Randomized Multicenter Trial

Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence (HORSE)

Purpose

The purpose of this study is to determine the role of surgery followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) versus surgery

alone in patients with platinum-sensitive first recurrence of ovarian cancer. Moreover it is a prospective randomized multicenter trial, aimed

to investigate the prognostic role of surgery plus HIPEC versus surgery alone in terms of progression free interval, overall survival, morbidity

and mortality, second recurrence pattern, quality of life with EORTC QLQ-C30 and QLQ OV28 questionnaires.

This study is currently recruiting participants.

Verified February 2012 by Catholic University of the Sacred Heart

First Received on February 20, 2012. Last Updated on February 28, 2012 History of Changes

Sponsor:	Catholic University of the Sacred Heart
Information provided by (Responsible Party):	Prof. Giovanni Scambia, Catholic University of the Sacred Heart
ClinicalTrials.gov Identifier:	NCT01539785

UH Case Medical Center Offers New Therapy (HIPEC) for Gynecologic Cancer Patients -- CLEVELAND, Jan. 20, 2012 /PRNewswire/

CLEVELAND, Jan. 20, 2012 /PRNewswire/ -- Patients with gynecologic cancer have new hope in a novel technology now offered at the Seidman Cancer Center at University Hospitals (UH) Case Medical Center. A team of cancer specialists, led by Robert DeBernardo, MD, is among the first in the nation to launch a dedicated program using Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to treat ovarian, endometrial and select other cancers....."